Pfizer
NEWS
There was a fair amount of clinical trial news last week. Here’s a look.
Three days after U.S. Food and Drug Administration staff raised safety concerns over Pfizer’s and Eli Lilly’s NGF osteoarthritis drug tanezumab, an advisory panel has also posted its own objections.
With oncology drugs clocking a disheartening 3.4% success rate, some good news in the field is always appreciated.
Myovant Sciences and Pfizer announced positive results from the Phase III LIBERTY trial of relugolix combination therapy in women with uterine fibroids.
With the rise of mutant strains of SARS-CoV-2 and the unlikelihood of 100% compliance in getting vaccines out, investigators are focusing on developing even better vaccines and new drugs that might be able to knock back the disease. Here’s a look.
With widespread distribution of various vaccines against COVID-19 vaccine ongoing, companies are still refining their vaccines and therapies and generating new data. Here’s a look at two recent updates.
A briefing document from the U.S. FDA cites critical safety concerns with Pfizer and Eli Lilly’s anti-NGF osteoarthritis drug tanezumab, despite the fact that clinical trials have demonstrated the agent can help patients with osteoarthritis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
JOBS
IN THE PRESS